11 August 2017
In its financial report for Q2 2017, Teva announced that it was curtailing the activities in 45 countries.
In this regard, Teva Russia made an official comment to clarify the following: the countries scheduled for business closure are mostly located in Africa and the Middle East, where the company’s presence is small.
The Russian office continues to operate as usual, without any changes in its operating activities. The company is successfully developing the local manufacturing at its plant in Yaroslavl and has long-term plans for the Russian market, which remains a strategic one for Teva.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024